Literature DB >> 21394033

Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: results of a claims data-based 1-year follow-up.

Hendrik van den Bussche1, Hanna Kaduszkiewicz, Daniela Koller, Marion Eisele, Susanne Steinmann, Gerd Glaeske, Birgitt Wiese.   

Abstract

We examined the patterns of prescription for antidementia drugs by German physicians with special reference to source of prescription, appropriateness of drugs and dosages and continuity of prescription patterns. The study is based on claims data of all 1848 incident cases in persons aged 65 years and older from a nationwide operating statutory health insurance company in the years 2004-2006. Inclusion criteria were one International Statistical Classification of Diseases and Related Health Problems 10th Revision code for dementia in at least three of four consecutive quarters and four quarters without such a code beforehand. Defined daily doses were used to quantify the prescription size. Data analysis used univariate and multivariate techniques. The majority of incident dementia cases in general and Alzheimer's disease cases in particular did not receive medication in conformity with the guidelines during the year after incidence. Inappropriate prescription was related to not visiting a specialist, living in urban areas, age and comorbidity. Further research is needed both on reasons for nonprescription among professionals and for discontinuation by the patients. In addition, the problems of practicability and implementation of guidelines deserve more attention.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21394033     DOI: 10.1097/YIC.0b013e328344c600

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  12 in total

Review 1.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 2.  Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors.

Authors:  Colleen J Maxwell; Kathryn Stock; Dallas Seitz; Nathan Herrmann
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

3.  Potentially Inappropriate Medications Pre- and Post-Diagnosis of Major Neurocognitive Disorders Among Older People in Sweden: A Register-Based, 6-Year Longitudinal Study.

Authors:  Eva Sönnerstam; Maria Gustafsson; Hugo Lövheim; Maria Sjölander
Journal:  Drugs Aging       Date:  2022-06-03       Impact factor: 4.271

4.  Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study.

Authors:  Daniela Koller; Tammy Hua; Julie P W Bynum
Journal:  J Am Geriatr Soc       Date:  2016-06-24       Impact factor: 5.562

5.  Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia.

Authors:  Falk Hoffmann; Hendrik van den Bussche; Birgitt Wiese; Gerhard Schön; Daniela Koller; Marion Eisele; Gerd Glaeske; Martin Scherer; Hanna Kaduszkiewicz
Journal:  BMC Psychiatry       Date:  2011-12-06       Impact factor: 3.630

6.  Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use.

Authors:  Markus Wübbeler; Diana Wucherer; Johannes Hertel; Bernhard Michalowsky; Steffen Heinrich; Saskia Meyer; Susanne Schaefer-Walkmann; Wolfgang Hoffmann; Jochen René Thyrian
Journal:  BMC Health Serv Res       Date:  2015-05-22       Impact factor: 2.655

7.  Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany.

Authors:  Sittah Czeche; Katrin Schüssel; Alexandra Franzmann; Martin Burkart; Martin Schulz
Journal:  BMC Complement Altern Med       Date:  2013-10-24       Impact factor: 3.659

8.  Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.

Authors:  Heidi Taipale; Antti Tanskanen; Marjaana Koponen; Anna-Maija Tolppanen; Jari Tiihonen; Sirpa Hartikainen
Journal:  Int Clin Psychopharmacol       Date:  2014-07       Impact factor: 1.659

9.  Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data.

Authors:  Larissa Schwarzkopf; Petra Menn; Reiner Leidl; Elmar Graessel; Rolf Holle
Journal:  BMC Health Serv Res       Date:  2013-01-03       Impact factor: 2.655

Review 10.  'Big data' in mental health research: current status and emerging possibilities.

Authors:  Robert Stewart; Katrina Davis
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-07-27       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.